Enterprise Value

3.248B

Cash

279.9M

Avg Qtr Burn

-90.46M

Short % of Float

21.99%

Insider Ownership

0.56%

Institutional Own.

89.18%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

Iovance TIL (LN-145) Details
Non-small cell lung carcinoma, Cancer

Phase 2

Data readout

Iovance TIL (LN-145) +/- pembrolizumab Details
Cancer, Non-small cell lung carcinoma

Phase 2

Data readout

Lifileucel Details
Cancer, Cervical cancer

Phase 2

Update

Iovance TIL (LN-145) Details
Cancer, Endometrial cancer

Phase 2

Initiation

IOV-4001 Details
Non-small cell lung carcinoma, Cancer, Melanoma

Phase 1/2

Update